论文部分内容阅读
目的:分析研究紫杉醇联合顺铂治疗中晚期食道癌的疗效及安全性。方法:从2009年10月到2014年11月,于我院接受治疗的中晚期食道癌患者共56例。以数字法随机分成观察组(28例)和对照组(28例)。对两组实施不同的化疗方案治疗,观察组采用紫杉醇联合顺铂的化疗方案,对照组采用氟尿嘧啶联合顺铂的化疗方案治疗。化疗结束后,对比两组疗效以及不良反应情况。结果:观察组的有效率和病情控制率均显著高于对照组,差异具有统计学意义(P<0.05)。观察组骨髓抑制、胃肠道反应发生率均显著低于对照组,差异具有统计学意义(P<0.05)。结论:采用紫杉醇联合顺铂的方案治疗中晚期食道癌患者,疗效显著,且治疗后不良反应发生率低,值得推广。
Objective: To analyze the efficacy and safety of paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer. Methods: From October 2009 to November 2014, a total of 56 patients with advanced esophageal cancer treated in our hospital. Numerically divided into observation group (28 cases) and control group (28 cases). The two groups were treated with different chemotherapy, the observation group with paclitaxel combined with cisplatin chemotherapy, the control group with fluorouracil and cisplatin chemotherapy regimen. After chemotherapy, the two groups were compared for efficacy and adverse reactions. Results: The effective rate and disease control rate in the observation group were significantly higher than those in the control group, the difference was statistically significant (P <0.05). The incidence of bone marrow suppression and gastrointestinal reaction in the observation group was significantly lower than that in the control group, with statistical significance (P <0.05). Conclusion: Paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer patients, the effect was significant, and the incidence of adverse reactions after treatment is worthy of promotion.